ABC Farma - Artificial Intelligence Doctor

Aveir VR Prognosis and Exit Block Analysis

Question 1

What is the cardiac prognosis of an Aveir VR with output voltage at 4.0 V at 0.4 ms?

Answer

There is no published data directly linking a programmed output of 4.0 V @ 0.4 ms in the Abbott AVEIR™ VR Leadless Pacemaker to a defined “cardiac prognosis” (e.g., mortality, heart-failure progression, or ventricular remodeling). However, clinical and engineering interpretation provide insight:

• The pivotal AVEIR IDE study defined successful performance as a pacing-capture threshold ≤ 2.0 V @ 0.4 ms and R-wave ≥ 5 mV.
• A threshold of 4.0 V is considerably above that target, implying higher myocardial stimulation requirements and thus greater energy consumption per pulse.
• Higher output shortens projected battery longevity approximately with the square of the voltage. Scaling from the ~10 yr baseline at 2.5 V @ 0.4 ms, 4.0 V corresponds to roughly 4 yrs at 100% pacing, 6–8 yrs at 50%, and 10–15 yrs at low pacing burdens.
• Such programming does not imply poorer cardiac outcomes, but it signals the need for close follow-up of thresholds, impedance, sensing, and pacing burden to optimize longevity and ensure capture safety margins.

In summary, 4.0 V @ 0.4 ms denotes an unusually high threshold that mainly impacts device longevity—not patient cardiac prognosis. Regular interrogation and possible re-programming after threshold stabilization are recommended.

Question 2

Can an exit block exist in leadless pacemakers with a BNP blood test of 87?

Answer

Yes. “Exit block” (failure of myocardial capture despite a pacing stimulus) can occur in leadless pacemakers, although it is rare (≈ 1–2% capture-related issues in large Micra/AVEIR registries, and < 1% true dislodgement). Documented causes include suboptimal fixation, rising thresholds, myocardial scar, or device displacement.

A BNP level of ≈ 87 pg/mL is generally within normal or mildly elevated range and reflects minimal ventricular wall stress. It does not predict nor exclude exit block, since BNP reflects hemodynamic load rather than electrical capture. Thus, both can coexist: a device may fail to capture while the patient’s BNP remains low.

When exit block or non-capture is suspected, the correct evaluation path is:

1. Device interrogation – capture threshold, impedance, and sensing amplitude trends.
2. Imaging (fluoroscopy or echo) to confirm fixation and rule out migration.
3. Clinical rhythm monitoring for pauses or bradycardia symptoms.

Management may include re-programming to higher output, repositioning, or (rarely) device retrieval/re-implantation. BNP testing contributes to global heart-failure assessment but is unrelated to the pacing interface itself.

Prepared by Artificial Intelligence Doctor / ABC Farma – Educational medical content, November 2025.